Skip to content

Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04055571
Enrollment
500
Registered
2019-08-13
Start date
2019-03-05
Completion date
2028-01-30
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign or Malignant Pancreatic Diseases

Brief summary

This study will be a retrospective chart review of patients who have been diagnosed with the benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, Texas(TX). The investigators plan to conduct an analysis of patients meeting the inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is, surgery fellows, office staff and clinical research coordinator who are delegated to do by the PI. Data will be obtained by looking through either investigator's patients or through a national database. Data will be analyzed primarily by the study conductors.

Detailed description

It is reported in the literature that the treatment of any pancreatic disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The investigator's goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality, and morbidity. The main aim of this study is to evaluate and compare the outcomes from the investigator's decisions on multiple treatments of benign or malignant pancreatic diseases.There is a need to understand and improve the current diagnosis and treatment algorithm for pancreatic pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery. All past patients who were treated for a particular benign or malignant pancreatic disease process under evaluation from 2005 to present will be included in this study.

Interventions

None listed

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* • All patients diagnosed and treated for pancreatic diseases, benign or malignant from 2005 to present * Age ≥18 years

Exclusion criteria

* • Patients that are not diagnosed with or treated for pancreatic diseases * Age \< 18 years

Design outcomes

Primary

MeasureTime frameDescription
Overall survival2005 to 2019Number of patients who have been diagnosed with benign or malignant pancreatic disease

Countries

United States

Contacts

CONTACTCrystee Cooper, DHEd
CrysteeCooper@mhd.com214-947-1280
CONTACTNitasha Phatak, Ph.D.
NitashaPhatak@mhd.com214-947-4459
PRINCIPAL_INVESTIGATORDhiresh Jeyarajah, M.D.

Methodist Richardson Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026